Second One From Kite

Oct 19, 2017

The US Food and Drug Administration has approved a second gene therapy, this one from Kite Pharmaceuticals, the New York Times reports. The agency approved Novartis' Kymriah earlier this year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Recent Headlines from
Precision Oncology News

Verastem Oncology's Combination Therapy Advances in KRAS-Mutated Lung Cancer
Premium
Carisma Therapeutics Taps Into Innate Immune System to Extend CAR Therapy to Solid Tumors
Premium
Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows
Premium
With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients
Premium
Survey of Canadian Cancer Centers Sheds Light on Inequities in Biomarker Test Access
Premium

The Scan

Early Trial Responses

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Hurdles to Genomic Surveillance

Nature News writes that viral genomic surveillance in the US faces systemic issues.

Boosts Requested

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

PLOS Papers on Chronic Pain, Indigenous Populations in Mexico, SARS-CoV-2 Mutations

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Menu